文献速递肝病消化内镜

原发性胆汁性胆管炎患者门静脉高压的无创评估受胆汁淤积严重程度影响

Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2024-12-13

本研究纳入293例原发性胆汁性胆管炎合并代偿期进展性慢性肝病患者,评估无创检测排除高风险静脉曲张和临床显著门静脉高压的性能。结果显示RESIST标准漏诊高风险静脉曲张率最低(2.5%),胆汁淤积严重时Baveno VI和Expanded Baveno VI漏诊率升高,RESIST净获益最高。

要点

  • RESIST标准漏诊高风险静脉曲张率2.5%,低于Baveno VI的9.8%和Expanded Baveno VI的8.9%。
  • 碱性磷酸酶≥1.5倍正常上限时,Baveno VI和Expanded Baveno VI漏诊高风险静脉曲张率分别为15.5%和14.5%,RESIST为3.1%。
  • 符合Baveno VII低临床显著门静脉高压风险标准的75例患者中,14例(18.7%)存在食管静脉曲张。

核心结论

  • 基于生化指标的RESIST标准排除高风险静脉曲张的净获益最高,优于基于弹性成像的标准。
  • 胆汁淤积严重程度影响无创检测在原发性胆汁性胆管炎合并代偿期进展性慢性肝病患者中排除高风险静脉曲张和临床显著门静脉高压的性能。

研究设计与样本

  • 研究纳入来自意大利原发性胆汁性胆管炎登记处和2个英国大容量原发性胆汁性胆管炎转诊中心的连续患者,共293例代偿期进展性慢性肝病。
  • 纳入标准为生化评估后6个月内接受上消化道内镜和瞬时弹性成像检查。
  • 评估RESIST、Baveno VI和Expanded Baveno VI标准排除高风险静脉曲张的性能,并按碱性磷酸酶水平(<或≥1.5倍正常上限)分层分析。
  • 进行决策曲线分析,并计算符合Baveno VII标准的患者中任何大小食管静脉曲张的患病率。

主要发现

  • RESIST标准漏诊高风险静脉曲张率最低(2.5%),Baveno VI为9.8%,Expanded Baveno VI为8.9%。
  • 碱性磷酸酶≥1.5倍正常上限的患者中,Baveno VI和Expanded Baveno VI漏诊高风险静脉曲张率分别为15.5%和14.5%,RESIST为3.1%。
  • 决策曲线分析显示,无论碱性磷酸酶水平如何,RESIST标准排除高风险静脉曲张的净获益最高。
  • 符合Baveno VII低临床显著门静脉高压风险标准的75例患者中,14例(18.7%)存在食管静脉曲张。

关键数值与推荐

  • RESIST标准漏诊高风险静脉曲张率2.5%,Baveno VI为9.8%,Expanded Baveno VI为8.9%。
  • 碱性磷酸酶≥1.5倍正常上限时,Baveno VI漏诊高风险静脉曲张率15.5%,Expanded Baveno VI为14.5%,RESIST为3.1%。
  • 符合Baveno VII低临床显著门静脉高压风险标准的75例患者中,14例(18.7%)存在食管静脉曲张。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Noninvasive tests (NITs) for ruling-out clinical significant portal hypertension (CSPH) and high-risk varices (HRVs) in patients with primary biliary cholangitis (PBC) and compensated advanced chronic liver disease (cACLD) are lacking. We evaluated NITs in these patients and the influence of cholestasis on their performance. METHODS: Consecutive patients from the "Italian PBC registry" and 2 United Kingdom large-volume PBC referral centers with upper endoscopy within 6 months from biochemical evaluation and transient elastography were included. Rete Sicilia Selezione Terapia (RESIST), Baveno VI (BVI), and Expanded Baveno VI (EBVI) criteria for ruling out HRV were assessed according to alkaline phosphatase (ALP) levels (< or ≥1.5 × upper limit of normal). Decision curve analysis was performed. Prevalence of any sized esophageal varices among patients fitting Baveno VII (BVII) criteria was also calculated. RESULTS: The final cohort consisted of 293 patients with cACLD. RESIST criteria were associated with the lowest rate of missed HRV (2.5% vs 9.8% for BVI and 8.9% for EBVI). In patients with ALP levels ≥1.5 × upper limit of normal, BVI and EBVI missed a higher rate of HRV (15.5% and 14.5%, respectively) than RESIST (3.1%). Decision curve analysis demonstrated the highest net benefit of RESIST criteria for ruling out HRV, regardless of ALP levels. Among 75 patients classified as low risk of CSPH according to BVII, 14 (18.7%) showed esophageal varices. CONCLUSIONS: Biochemical-based RESIST criteria demonstrate the highest net benefit compared with elastography-based criteria for ruling out HRV. The severity of cholestasis affects NITs performance to rule out HRV and CSPH in patients with PBC and cACLD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Calvaruso V, Celsa C, Cristoferi L, et al. Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis. Clin Gastroenterol Hepatol. 2024. PMID: 39674236. doi:10.1016/j.cgh.2024.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。